SCHEMBL6858593

SCHEMBL6858593

COc1ccc(OC)c(C(=O)C2C(c3ccc(OC)c(N)c3)C2(Cl)Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.44
ALDH1A1 P00352 4/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
THRB P10828 1/20 0.44
HTT P42858 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
LMNA P02545 2/20 0.42
KDM4E B2RXH2 2/20 0.42
POLB P06746 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
RAB9A P51151 1/20 0.37
SLC9A1 P19634 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6314156 0.92 MAPT (0.40) MAPTALDH1A1MEN1KMT2ATHRB
SCHEMBL6316241 0.92 POLB (0.42) MAPTALDH1A1MEN1KMT2ATHRB
SCHEMBL6321116 0.89 MAPT (0.38) MAPTALDH1A1MEN1KMT2ATHRB
SCHEMBL7125986 0.89 MAPT (0.49) MAPTALDH1A1MEN1KMT2AHTT
SCHEMBL6853088 0.87 MAPT (0.44) MAPTALDH1A1MEN1KMT2AHTT
SCHEMBL6853300 0.87 ALDH1A1 (0.46) MAPTALDH1A1MEN1KMT2ATHRB
SCHEMBL6861248 0.84 POLB (0.43) MAPTALDH1A1MEN1KMT2AHTT
SCHEMBL7034852 0.84 MAPT (0.41) MAPTALDH1A1MEN1KMT2AHTT
SCHEMBL6859785 0.83 KMT2A (0.49) MAPTALDH1A1MEN1KMT2AHTT
SCHEMBL7119970 0.83 TUBB1 (0.50) MAPTALDH1A1MEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1453783-A1 SUBSTITUTED ARYL-CYCLOALKANES, AND USE THEREOF AS ANTICANCER AGENTS Aventis Pharma S.A. (FR) 2004-09-08 EP disclosed
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof AVENTIS PHARMA S.A. (FR) 2003-08-07 US disclosed
WO-2003048096-A1 SUBSTITUTED ARYL-CYCLOALKANES, AND USE THEREOF AS ANTICANCER AGENTS AVENTIS PHARMA S.A. (FR) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof ABL1, MCL1, AHR MAPT 4538/4885ALDH1A1 682/4885MEN1 2077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.